Healthcare Most Active Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Johnson & Johnson (NYSE:JNJ), MannKind Corporation (NASDAQ:MNKD), Abbott Laboratories (NYSE:ABT)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is one of half a dozen drugmakers that have been rolling out generics of Eli Lilly’s ($LLY) top-selling blockbuster Cymbalta. The others are going to roll past the Israeli drugmaker after it recalled more than 1 million bottles of the antidepressant. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -0.76% in last session and finished the day at … Continue reading Healthcare Most Active Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Johnson & Johnson (NYSE:JNJ), MannKind Corporation (NASDAQ:MNKD), Abbott Laboratories (NYSE:ABT)

Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Amgen Inc. (NASDAQ:AMGN) carries a Zacks Rank #1 (Strong Buy). Amgen, Inc. (NASDAQ:AMGN) stock performance was -1.90% in last session and finished the day at $111.94. Traded volume was 7.26million shares in the last session and the average volume of the stock remained 3.63million shares. The beta of the stock remained 0.51. Amgen, Inc. (NASDAQ:AMGN) insider ownership is 0.10%. Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biopharmaceutical … Continue reading Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at … Continue reading Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session and finished the day at $65.48. Traded volume was 43.15million … Continue reading Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

On Monday, Johnson & Johnson (NYSE:JNJ) announced that it accepted the binding offer from The Carlyle Group (NASDAQ:CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. Johnson & Johnson (NYSE:JNJ) stock performance was 0.16% in last session and finished the day at $98.42. Traded volume was 10.31million shares in the … Continue reading Healthcare active runners: Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) had its price objective reduced by Cowen and Company from $5.50 to $5.00 in a report released on Wednesday,Stock Ratings News reports. Analysts at Piper Jaffray downgraded shares of MannKind Corporation (NASDAQ:MNKD) from a neutral rating to an underweight rating in a research note on Monday. MannKind Corporation (NASDAQ:MNKD) stock performance was -0.86% in last session and finished the day at $6.93. … Continue reading Biotech Runners: MannKind Corporation (NASDAQ:MNKD), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), CytRx Corporation (NASDAQ:CYTR)